GB
Highly rated in
23
conditions

Dr. Gregory P. Brandt

SIU Healthcare
Springfield, IL
Highly rated in
23
conditions
Specialties:Pediatric Hematology Oncology | Pediatrics
Experience:35 Years
Clinical Trials:Currently Recruiting for 24 Trials
Accepts:New Patients
Highly rated in
23
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Gregory P. Brandt's experience treating your condition:
About Dr. Gregory P. Brandt

Gregory Brandt is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Springfield, Illinois. Brandt has been practicing medicine for over 35 years and is highly rated in 23 conditions, according to our data. His top areas of expertise are Langerhans Cell Histiocytosis, Desmoplastic Small Round Cell Tumor, Histiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in Illinois. Brandt is currently accepting new patients.

His participating in 59 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Gregory P. Brandt it is best to call his office and ask if your insurance is accepted.

Dr. Gregory P. Brandt accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Health Alliance
Call to see if your plan is accepted.
Locations
400 N 9th St, Springfield, IL 62702
Other Locations
301 N 8th St, Springfield, IL 62701
441 W Hay St, Decatur, IL 62526
Background & Education
Graduate Institution
Saint Louis University School Of Medicine, 1988
Specialties
Pediatric Hematology Oncology
Pediatrics
Licenses
Pediatric Hematology-Oncology in IL
Hospital Affiliations
HSHS Holy Family Hospital
HSHS St Johns Hospital
HSHS St Josephs Hospital - Breese
Springfield Memorial Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

59 Clinical Trials
Renal Tumors Classification, Biology, and Banking Study
Enrollment Status: Recruiting
Publish Date: September 07, 2022
Intervention Type: Other
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Recruiting
Publish Date: December 06, 2022
Intervention Type: Procedure, Drug, Other
Study Drugs: EnsartinibErdafitinibLarotrectinibOlaparibPalbociclibSamotolisibSelpercatinibSelumetinib SulfateTazemetostatTipifarnibUlixertinibVemurafenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Enrollment Status: Recruiting
Publish Date: December 01, 2022
Intervention Type: Procedure, Drug
Study Drugs: LarotrectinibLarotrectinib Sulfate
Study Phase: Phase 2
StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Other, Behavioral, Device
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Enrollment Status: Recruiting
Publish Date: December 09, 2022
Intervention Type: Procedure, Drug
Study Drug: Samotolisib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Enrollment Status: Recruiting
Publish Date: December 13, 2022
Intervention Type: Procedure, Drug
Study Drug: Tipifarnib
Study Phase: Phase 2
Establishing Continuous Cell Lines and Xenografts From Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies
Enrollment Status: Recruiting
Publish Date: August 08, 2022
Intervention Type: Other
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Other, Procedure, Drug
Study Drugs: CarboplatinSelumetinib SulfateVincristine Sulfate
Study Phase: Phase 3
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Enrollment Status: Recruiting
Publish Date: May 04, 2022
Intervention Type: Procedure, Drug, Behavioral
Study Drugs: AsparaginaseErwinia AsparaginaseCytarabineDaunorubicinDexrazoxaneEtoposideGemtuzumabGilteritinibLiposomal DaunorubicinLiposomal CytarabineMethotrexateMitoxantroneHydrocortisone
Study Phase: Phase 3
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: October 21, 2022
Intervention Type: Other
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Radiation, Drug, Procedure
Study Drugs: CarboplatinCyclophosphamideDoxorubicinEtoposideIfosfamideIrinotecanTopotecanVincristine
Study Phase: Phase 2
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: BleomycinBleomycin SulfateCarboplatinCisplatinEtoposideEtoposide Phosphate
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Enrollment Status: Recruiting
Publish Date: December 08, 2022
Intervention Type: Drug
Study Drug: Ivosidenib
Study Phase: Phase 2
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Procedure, Drug, Biological, Radiation
Study Drugs: CyclophosphamideDoxorubicin HydrochlorideEtoposide PhosphateFilgrastimNivolumabPegfilgrastimPrednisolonePrednisoneRituximabRituximab+Hyaluronidase HumanVincristine Sulfate
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Other, Procedure, Drug
Study Drugs: CarboplatinSelumetinib SulfateVincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Recruiting
Publish Date: September 16, 2022
Intervention Type: Drug, Radiation, Other
Study Drugs: CisplatinCyclophosphamideLomustineVincristineVincristine Sulfate
Study Phase: Phase 2
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia AsparaginaseBlinatumomabCyclophosphamideCytarabineDexamethasoneDoxorubicin HydrochlorideLeucovorin CalciumMercaptopurineMethotrexatePegaspargasePrednisolonePrednisoneThioguanineVincristine Sulfate
Study Phase: Phase 3
A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Recruiting
Publish Date: September 19, 2022
Intervention Type: Drug, Procedure, Biological, Other
Study Drugs: CyclophosphamideCytarabineDaunorubicin HydrochlorideDexamethasoneDexrazoxane HydrochlorideDoxorubicinEtoposideFilgrastimIfosfamideImatinib MesylateLeucovorin CalciumMercaptopurineMethotrexateMethylprednisolonePegaspargasePrednisoloneHydrocortisoneThioguanineVincristine Sulfate
Study Phase: Phase 3
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: November 03, 2022
Intervention Type: Drug, Biological, Radiation, Other
Study Drugs: CalaspargaseCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinInotuzumabLeucovorin6-MercaptopurineMethotrexatePegaspargasePrednisoloneThioguanineVincristine
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Drug, Other, Procedure
Study Drugs: CarboplatinCisplatinDoxorubicinEtoposideFluorouracilGemcitabineIrinotecanOxaliplatinSorafenibVincristine Sulfate
Study Phase: Phase 2/Phase 3
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Recruiting
Publish Date: September 19, 2022
Intervention Type: Drug, Procedure, Biological
Study Drugs: CyclophosphamideCytarabineInotuzumabLeucovorin6-MercaptopurinePegaspargaseVincristine
Study Phase: Phase 2
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Enrollment Status: Recruiting
Publish Date: November 30, 2022
Intervention Type: Other, Procedure, Drug
Study Drug: Tyrosine Kinase Inhibitor
Study Phase: Phase 2
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
Enrollment Status: Completed
Publish Date: July 19, 2018
Intervention Type: Other
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active, not recruiting
Publish Date: February 23, 2022
Intervention Type: Drug, Radiation
Study Drugs: BortezomibCyclophosphamideCytarabineDaunorubicinDaunorubicin HydrochlorideDexamethasoneDoxorubicinDoxorubicinEtoposideHydrocortisone Sodium SuccinateIfosfamideLeucovorin CalciumMercaptopurineMethotrexatePegaspargaseThioguanineVincristineVincristine Sulfate
Study Phase: Phase 3
A COG Study for Collecting and Banking Ewing Sarcoma Specimens
Enrollment Status: Active, not recruiting
Publish Date: March 24, 2022
Intervention Type: Other
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Active, not recruiting
Publish Date: December 07, 2022
Intervention Type: Drug, Other, Radiation
Study Drugs: ClofarabineCyclophosphamideCytarabineDasatinibDaunorubicin HydrochlorideDexamethasoneDoxorubicin HydrochlorideEtoposideHydrocortisone Sodium SuccinateLeucovorin CalciumMercaptopurineMethotrexatePegaspargasePrednisoneThioguanineVincristine Sulfate
Study Phase: Phase 3
Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Active, not recruiting
Publish Date: March 24, 2022
Intervention Type: Other
Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Drug, Radiation, Procedure
Study Drugs: DoxorubicinIfosfamidePazopanib
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD
Enrollment Status: Active, not recruiting
Publish Date: September 19, 2022
Intervention Type: Other, Drug
Study Drugs: AsparaginaseBortezomibCytarabineDaunorubicinEtoposideMitoxantroneSorafenib
Study Phase: Phase 3
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
Enrollment Status: Active, not recruiting
Publish Date: March 21, 2022
Intervention Type: Drug, Radiation, Other
Study Drugs: CarboplatinCisplatinCyclophosphamideEtoposideVincristine
Study Phase: Phase 3
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active, not recruiting
Publish Date: July 12, 2022
Intervention Type: Other, Drug
Study Drugs: CyclophosphamideCytarabineDexamethasoneDoxorubicin HydrochlorideLeucovorin CalciumMercaptopurineMethotrexatePegaspargaseThioguanineVincristine Sulfate
Study Phase: Phase 3
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Enrollment Status: Active, not recruiting
Publish Date: November 17, 2022
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: CyclophosphamideDoxorubicinDoxorubicin HydrochlorideEtoposideEtoposide PhosphateGanitumabIfosfamideVincristineVincristine Sulfate
Study Phase: Phase 3
A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma
Enrollment Status: Completed
Publish Date: October 24, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: DinutuximabIrinotecan HydrochlorideSargramostimTemozolomideTemsirolimus
Study Phase: Phase 2
A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma
Enrollment Status: Active, not recruiting
Publish Date: November 17, 2022
Intervention Type: Other, Biological
Study Drugs: DinutuximabSargramostim
Study Phase: Phase 2
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
Enrollment Status: Active, not recruiting
Publish Date: December 15, 2022
Intervention Type: Drug
Study Drugs: Brentuximab VedotinCrizotinibCyclophosphamideCytarabineDexamethasoneDoxorubicin HydrochlorideEtoposideIfosfamideMethotrexate
Study Phase: Phase 2
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement
Enrollment Status: Active, not recruiting
Publish Date: October 14, 2022
Intervention Type: Drug, Other
Study Drugs: AzacitidineCyclophosphamideCytarabineDaunorubicinDexamethasoneHydrocortisoneLeucovorinMercaptopurineMethotrexatePEG-AsparaginasePrednisoloneThioguanineVincristine
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
Enrollment Status: Active, not recruiting
Publish Date: September 23, 2022
Intervention Type: Other, Drug
Study Drug: Vemurafenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Enrollment Status: Suspended
Publish Date: December 13, 2022
Intervention Type: Procedure, Other, Drug
Study Drug: Erdafitinib
Study Phase: Phase 2
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Enrollment Status: Completed
Publish Date: January 18, 2020
Intervention Type: Other
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Enrollment Status: Active, not recruiting
Publish Date: July 27, 2022
Intervention Type: Other, Drug
Study Drug: Palbociclib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Enrollment Status: Active, not recruiting
Publish Date: October 20, 2022
Intervention Type: Other, Drug
Study Drug: Ulixertinib
Study Phase: Phase 2
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active, not recruiting
Publish Date: December 06, 2022
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: AsparaginaseBlinatumomabCyclophosphamideCytarabineDexamethasoneEtoposideLeucovorin CalciumMercaptopurineMethotrexateMitoxantroneMitoxantrone HydrochloridePegaspargaseHydrocortisoneThioguanineVincristineVincristine Sulfate
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Active, not recruiting
Publish Date: September 19, 2022
Intervention Type: Drug, Other, Procedure
Study Drugs: CisplatinDexrazoxaneDoxorubicin HydrochlorideFluorouracilIrinotecan HydrochlorideTemsirolimusVincristine Sulfate
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Suspended
Publish Date: December 13, 2022
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Suspended
Publish Date: November 28, 2022
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: CyclophosphamideDactinomycinIrinotecan hydrochlorideTemsirolimusVincristine sulfateVinorelbine
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active, not recruiting
Publish Date: October 20, 2022
Intervention Type: Drug, Other
Study Drugs: AsparaginaseErwinia AsparaginaseCytarabineDaunorubicinEtoposideMitoxantroneThioguanine
Study Phase: Phase 3
View 26 Less Clinical Trials -
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
RG
Dr. Ruchika K. Goel
Pediatrics | Pediatric Hematology Oncology | Hematology Oncology
Highly rated in
6
conditions
Pediatrics
Pediatric Hematology Oncology
Hematology Oncology

Memorial Health

Siu Physicians And Surgeons Inc

Springfield, IL 
 0.8 mi

Ruchika Goel is a Pediatrics specialist and a Pediatric Hematologist Oncology expert in Springfield, Illinois. Goel has been practicing medicine for over 18 years and is highly rated in 6 conditions, according to our data. Her top areas of expertise are Hemolytic Transfusion Reaction, Anemia, Virilizing Ovarian Tumor, Thrombocytopenia, and Bone Marrow Transplant. She is licensed to treat patients in Illinois. Goel is currently accepting new patients.

JM
John J. Millichap
Dr. John J. Millichap
Neurology | Pediatrics | Child Neurology
Highly rated in
13
conditions
Neurology
Pediatrics
Child Neurology

Precision Epilepsy PLLC

IL 
 58.6 mi

John J. Millichap, MD is a Pediatric Neurologist and Epileptologist. His current clinical practice utilizes an innovative telehealth approach to the precision diagnosis and treatment of pediatric epilepsy. He is involved in multiple clinical trials for novel treatments for rare genetic epilepsies. Dr. Millichap is Chair of the Medical Advisory Council for the Epilepsy Foundation of Greater Chicago and a member of the Child Neurology Foundation’s Board of Directors. He is licensed to practice in multiple states nationwide.

BB
Dr. Beau J. Batton
Neonatology | Pediatrics
Highly rated in
1
conditions
Neonatology
Pediatrics

Hospital Sisters Health System

415 N 9th St, 
Springfield, IL 
 0.1 mi

Beau Batton is a Neonatologist and a Pediatrics expert in Springfield, Illinois. Batton is highly rated in 1 condition, according to our data. His top areas of expertise are Premature Infant, Gastroschisis, Intraventricular Hemorrhage of the Newborn, and Placental Insufficiency. He is licensed to treat patients in Ohio. Batton is currently accepting new patients.